Envoy Medical(US:COCH) Newsfile·2025-08-20 12:00Core Insights - Envoy Medical has secured three new patents in the U.S., Australia, and Hong Kong, enhancing its leadership in fully implantable hearing technology [2][3][6] - The patents are aimed at advancing next-generation cochlear implant solutions, providing patients with a discreet and continuous hearing experience [2][3] Patent Details - U.S. Patent No. 12,390,634 relates to a fully implantable modular cochlear implant system that includes a signal processor and an implantable battery or communication module [3] - Australian Patent No. 2022254630 focuses on electrode impedance diagnostics in cochlear implant systems, determining stimulation parameters based on impedance [3] - Hong Kong Patent No. 40101898 pertains to cochlear implant stimulation calibration, adjusting current flow based on testing circuit outputs [3] Company Vision and Strategy - The CEO of Envoy Medical, Brent Lucas, emphasized that the new patents are critical for redefining hearing restoration solutions and expanding the company's global patent portfolio [3][6] - The company aims to eliminate daily limitations faced by millions with hearing loss through innovative, fully implantable solutions [3][6] Product Overview - Envoy Medical's Acclaim Cochlear Implant is designed for severe to profound sensorineural hearing loss and is the first fully implanted cochlear implant [8] - The Esteem fully implanted active middle ear implant is the only FDA-approved device of its kind, providing 24/7 hearing capability without external components [9]